Skip to content

The Effect of Superficial Cervical Block Application on Postoperative Opioid Consumption in Patients Undergoing Anterior Cervical Discectomy Surgery

The Effect of Superficial Cervical Block Application on Postoperative Opioid Consumption in Patients Undergoing Anterior Cervical Discectomy Surgery

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06755736
Enrollment
48
Registered
2025-01-01
Start date
2025-01-06
Completion date
2025-09-01
Last updated
2026-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Superficial Cervical Block, Postoperative Pain

Keywords

superficial cervical block, anterior cervical discectomy, regional anesthesia

Brief summary

This randomized controlled trial aims to evaluate the effect of superficial cervical block on postoperative opioid consumption in patients undergoing anterior cervical discectomy surgery. Postoperative pain significantly impacts recovery and patient comfort in this type of surgery, where symptoms such as swallowing difficulties, occipito-cervical pain, and positional discomfort are common. While opioids are effective for pain control, their side effects, such as nausea, vomiting, and respiratory depression, may lead to complications, especially in cervical surgeries with potential airway risks. Superficial cervical block is a simple and safe regional anesthesia technique proven effective in managing pain after thyroid and carotid surgeries. However, its potential benefits in anterior cervical discectomy surgeries have not been extensively studied. Our hypothesis is that superficial cervical block can reduce postoperative opioid use and provide effective pain management for these patients. Additionally, investigators aim to compare opioid-related side effects and postoperative pain scores between groups with and without the block.

Detailed description

This prospective, randomized, double-blind, controlled trial is conducted at Medipol Mega University Hospital in patients undergoing microscopic anterior cervical discectomy and fusion (ACDF). The primary objective is to assess the effect of a superficial cervical plexus block on the incidence of requiring postoperative rescue analgesia. Secondary objectives are total cumulative tramadol consumption, the incidence of opioid-related adverse events (nausea, vomiting, pruritus) and postoperative Numerical Rating Scale (NRS) pain scores at rest and on movement. Patient selection: Eligible participants are aged 18-70 years with an American Society of Anesthesiologists (ASA) physical status of I-II, scheduled for unilateral single- or two-level microscopic ACDF under general anaesthesia. Exclusion criteria are bleeding diathesis, anticoagulant therapy, known local anaesthetic or opioid allergy, a history of chronic pain, infection of the skin at the puncture site, and refusal to participate. Study groups: Participants are randomly assigned to two groups. Group 1 (control) receives no regional block. Group 2 (intervention) receives a right-sided superficial cervical plexus block at the end of surgery, before awakening. Anaesthesia management: General anaesthesia is induced with intravenous propofol (2-3 mg/kg), fentanyl (1.5 mcg/kg) and rocuronium (0.6 mg/kg), and maintained with a remifentanil infusion (0.05-2 mcg/kg/min) and desflurane in an air-oxygen mixture. A remifentanil bolus (0.5 mcg/kg) is given if heart rate or mean arterial pressure rises more than 20% above the pre-induction baseline. All patients receive intravenous ondansetron 4 mg, paracetamol 1 g and tramadol 100 mg thirty minutes before surgery. Surgery is performed by the same team through a right-sided anterior cervical approach with a 3-4 cm transverse skin incision; no local anaesthetic or adrenaline infiltration is performed at the incision site in either group. Discectomy, neural decompression and interbody cage insertion are performed under the operating microscope. Block technique: Under ultrasound guidance, 20 mL of 0.25% bupivacaine is injected superficial to the investing layer of the deep cervical fascia at the posterior border of the sternocleidomastoid muscle. Postoperative evaluation: NRS pain scores at rest and on movement are recorded at 1, 3, 6, 12, 18 and 24 hours after surgery. Rescue analgesia (1 mg/kg intravenous tramadol) is given if the NRS score is 4 or above. Postoperative opioid consumption, adverse events (nausea, vomiting, pruritus) and block-related complications are recorded over the first 24 postoperative hours.

Interventions

In anterior cervical discectomy surgeries, superficial cervical block will be used for analgesia.

Sponsors

Medipol University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Aged between 18 and 70 years * American Society of Anesthesiologists (ASA) physical status I-II * Scheduled for unilateral single- or two-level microscopic anterior cervical discectomy and fusion (ACDF) under general anaesthesia

Exclusion criteria

* History of bleeding diathesis, * Receiving anticoagulant treatment, * Known local anesthetics and opioid allergy, * History of chronic pain * Infection of the skin at the site of the needle puncture, * Patients who do not accept the procedure

Design outcomes

Primary

MeasureTime frameDescription
Incidence of Requiring Postoperative Rescue Analgesiafirst 24 hours after the operationThe number of participants requiring tramadol as a rescue analgesic during the first 24 hours after surgery.

Secondary

MeasureTime frameDescription
Total Cumulative Tramadol Consumptionfirst 24 hours after the operationThe total cumulative dose of tramadol (measured in milligrams) consumed by participants for rescue analgesia.

Countries

Turkey (Türkiye)

Contacts

STUDY_DIRECTORBurak Ömür

Medipol University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 18, 2026